PAVmed (PAVM) Competitors $0.53 -0.05 (-8.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.53 +0.01 (+1.07%) As of 08/1/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PAVM vs. MODD, MLSS, NEPH, PYPD, POCI, COCH, PSTV, VVOS, CLGN, and FEMYShould you be buying PAVmed stock or one of its competitors? The main competitors of PAVmed include Modular Medical (MODD), Milestone Scientific (MLSS), Nephros (NEPH), PolyPid (PYPD), Precision Optics (POCI), Envoy Medical (COCH), Plus Therapeutics (PSTV), Vivos Therapeutics (VVOS), CollPlant Biotechnologies (CLGN), and Femasys (FEMY). These companies are all part of the "medical equipment" industry. PAVmed vs. Its Competitors Modular Medical Milestone Scientific Nephros PolyPid Precision Optics Envoy Medical Plus Therapeutics Vivos Therapeutics CollPlant Biotechnologies Femasys Modular Medical (NASDAQ:MODD) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership. Does the media refer more to MODD or PAVM? In the previous week, PAVmed had 3 more articles in the media than Modular Medical. MarketBeat recorded 3 mentions for PAVmed and 0 mentions for Modular Medical. PAVmed's average media sentiment score of 0.17 beat Modular Medical's score of 0.00 indicating that PAVmed is being referred to more favorably in the news media. Company Overall Sentiment Modular Medical Neutral PAVmed Neutral Do analysts rate MODD or PAVM? PAVmed has a consensus target price of $19.00, suggesting a potential upside of 3,516.29%. Given PAVmed's stronger consensus rating and higher probable upside, analysts clearly believe PAVmed is more favorable than Modular Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Modular Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PAVmed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MODD or PAVM more profitable? PAVmed has a net margin of 3,711.54% compared to Modular Medical's net margin of 0.00%. PAVmed's return on equity of 0.00% beat Modular Medical's return on equity.Company Net Margins Return on Equity Return on Assets Modular MedicalN/A -178.13% -151.42% PAVmed 3,711.54%N/A -42.29% Do institutionals and insiders hold more shares of MODD or PAVM? 27.5% of Modular Medical shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 20.5% of Modular Medical shares are held by insiders. Comparatively, 7.3% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, MODD or PAVM? PAVmed has higher revenue and earnings than Modular Medical. Modular Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModular MedicalN/AN/A-$18.82M-$0.51-1.40PAVmed$2.99M3.00$39.79M$0.710.74 Which has more risk & volatility, MODD or PAVM? Modular Medical has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. SummaryPAVmed beats Modular Medical on 13 of the 15 factors compared between the two stocks. Get PAVmed News Delivered to You Automatically Sign up to receive the latest news and ratings for PAVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PAVM vs. The Competition Export to ExcelMetricPAVmedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.84M$6.70B$5.48B$9.54BDividend YieldN/A1.32%4.73%4.09%P/E Ratio0.7420.9428.8623.83Price / Sales3.0054.12371.7266.14Price / CashN/A20.5035.4557.96Price / Book-0.574.468.275.54Net Income$39.79M$174.54M$3.25B$259.28M7 Day Performance-9.69%-5.27%-3.73%-4.68%1 Month Performance-11.10%-3.94%4.29%4.36%1 Year Performance-34.33%8.26%25.87%17.89% PAVmed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PAVMPAVmed4.4357 of 5 stars$0.53-8.7%$19.00+3,516.3%-34.5%$9.84M$2.99M0.7490News CoveragePositive NewsMODDModular Medical0.4917 of 5 stars$0.70-2.0%N/A-53.0%$38.73MN/A-1.3720Positive NewsGap DownMLSSMilestone Scientific2.0388 of 5 stars$0.49-17.4%$1.25+156.6%-55.5%$38.23M$8.61M-6.9630News CoverageNEPHNephros1.7341 of 5 stars$3.60+0.8%$5.00+38.9%+52.6%$37.84M$14.16M51.4430News CoveragePositive NewsUpcoming EarningsPYPDPolyPid2.2803 of 5 stars$3.64-1.1%$11.80+224.2%-6.6%$37.50MN/A-0.8580POCIPrecision Optics0.2066 of 5 stars$4.70-2.1%N/A-23.8%$36.80M$19.10M-5.2880Positive NewsCOCHEnvoy Medical1.9349 of 5 stars$1.53-1.9%$9.25+504.6%-37.2%$33.27M$220K-1.1134News CoveragePositive NewsEarnings ReportGap UpPSTVPlus Therapeutics2.194 of 5 stars$0.58+9.4%$10.83+1,768.8%-67.5%$32.05M$5.82M-0.2020Gap UpVVOSVivos Therapeutics0.4445 of 5 stars$4.72-9.9%$4.82+2.0%+138.7%$30.86M$14.63M-2.73160Analyst UpgradeShort Interest ↑Gap DownCLGNCollPlant Biotechnologies2.14 of 5 stars$2.33+0.9%$11.50+393.6%-48.3%$29.37M$510K-1.9170Positive NewsFEMYFemasys2.7852 of 5 stars$0.87-3.9%$8.67+901.8%-27.5%$29.27M$1.63M-0.9530Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Modular Medical Competitors Milestone Scientific Competitors Nephros Competitors PolyPid Competitors Precision Optics Competitors Envoy Medical Competitors Plus Therapeutics Competitors Vivos Therapeutics Competitors CollPlant Biotechnologies Competitors Femasys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PAVM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PAVmed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PAVmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PAVM Stock Alerts